Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Der Internist|November 12, 2005
[Molecular diagnosis of diabetes mellitus]U C Broedl, B Göke
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|March 14, 2009
[Diabetes mellitus - perioperative management]P Rittler, U C Broedl, W Hartl, et al.
Diabetes, Obesity & Metabolism|July 5, 2016
Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trialsA Salsali, G Kim, H J Woerle, et al.
Diabetes, Obesity & Metabolism|October 30, 2015
Mixed-effects modelling to quantify the effect of empagliflozin on renal glucose reabsorption in patients with type 2 diabetesJ Mondick, M Riggs, T Sasaki, et al.
Diabetes, Obesity & Metabolism|July 18, 2013
Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairmentS Macha, M Mattheus, A Halabi, et al.
Diabetes, Obesity & Metabolism|June 5, 2015
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trialJ Rosenstock, A Jelaska, C Zeller, et al.
Diabetes, Obesity & Metabolism|April 2, 2015
Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trialS Ross, C Thamer, J Cescutti, et al.
Diabetes, Obesity & Metabolism|July 18, 2013
Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairmentS Macha, P Rose, M Mattheus, et al.
Diabetes, Obesity & Metabolism|August 3, 2013
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trialC S Kovacs, V Seshiah, R Swallow, et al.
Diabetes, Obesity & Metabolism|September 8, 2015
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesR Chilton, I Tikkanen, C P Cannon, et al.
Pageof 2